Delivery of a peptide via poly(d,l-lactic-co-glycolic) acid nanoparticles enhances its dendritic cell-stimulatory capacity

Corbin Clawson, Chien Tze Huang, Diahnn Futalan, Daniel Martin Seible, Rebecca Saenz, Marie Larsson, Wenxue Ma, Boris Minev, Fiona Zhang, Mihri Ozkan, Cengiz Ozkan, Sadik Esener, Davorka Messmer

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Nanoparticles (NPs) are attractive carriers for vaccines. We have previously shown that a short peptide (Hp91) activates dendritic cells (DCs), which are critical for initiation of immune responses. In an effort to develop Hp91 as a vaccine adjuvant with NP carriers, we evaluated its activity when encapsulated in or conjugated to the surface of poly(d,. l-lactic-. co-glycolic) acid (PLGA) NPs. We found that Hp91, when encapsulated in or conjugated to the surface of PLGA-NPs, not only activates both human and mouse DCs, but is in fact more potent than free Hp91. Hp91 packaged within NPs was about fivefold more potent than the free peptide, and Hp91 conjugated to the surface of NPs was ~20-fold more potent than free Hp91. Because of their capacity to activate DCs, such NP-Hp91 systems are promising as delivery vehicles for subunit vaccines against infectious disease or cancer. From the Clinical Editor: In this paper, nanoparticle-based dendritic cell activating vaccines are described and discussed. The authors report that the presented PLGA NP based vaccine constructs increase the potency of the studied vaccine by up to 20-fold, making them promising as delivery vehicles for subunit vaccines against infectious diseases or cancer.

Original languageEnglish (US)
Pages (from-to)651-661
Number of pages11
JournalNanomedicine: Nanotechnology, Biology, and Medicine
Volume6
Issue number5
DOIs
StatePublished - Oct 2010
Externally publishedYes

Fingerprint

glycolic acid
Nanoparticles
Dendritic Cells
Peptides
Vaccines
Milk
Acids
Subunit Vaccines
Communicable Diseases
Vaccine Potency

Keywords

  • Dendritic cells
  • HMGB1
  • Immune stimulation
  • Peptide conjugation
  • PLGA nanoparticles

ASJC Scopus subject areas

  • Molecular Medicine
  • Bioengineering
  • Biomedical Engineering
  • Materials Science(all)
  • Medicine (miscellaneous)
  • Pharmaceutical Science

Cite this

Delivery of a peptide via poly(d,l-lactic-co-glycolic) acid nanoparticles enhances its dendritic cell-stimulatory capacity. / Clawson, Corbin; Huang, Chien Tze; Futalan, Diahnn; Martin Seible, Daniel; Saenz, Rebecca; Larsson, Marie; Ma, Wenxue; Minev, Boris; Zhang, Fiona; Ozkan, Mihri; Ozkan, Cengiz; Esener, Sadik; Messmer, Davorka.

In: Nanomedicine: Nanotechnology, Biology, and Medicine, Vol. 6, No. 5, 10.2010, p. 651-661.

Research output: Contribution to journalArticle

Clawson, C, Huang, CT, Futalan, D, Martin Seible, D, Saenz, R, Larsson, M, Ma, W, Minev, B, Zhang, F, Ozkan, M, Ozkan, C, Esener, S & Messmer, D 2010, 'Delivery of a peptide via poly(d,l-lactic-co-glycolic) acid nanoparticles enhances its dendritic cell-stimulatory capacity', Nanomedicine: Nanotechnology, Biology, and Medicine, vol. 6, no. 5, pp. 651-661. https://doi.org/10.1016/j.nano.2010.03.001
Clawson, Corbin ; Huang, Chien Tze ; Futalan, Diahnn ; Martin Seible, Daniel ; Saenz, Rebecca ; Larsson, Marie ; Ma, Wenxue ; Minev, Boris ; Zhang, Fiona ; Ozkan, Mihri ; Ozkan, Cengiz ; Esener, Sadik ; Messmer, Davorka. / Delivery of a peptide via poly(d,l-lactic-co-glycolic) acid nanoparticles enhances its dendritic cell-stimulatory capacity. In: Nanomedicine: Nanotechnology, Biology, and Medicine. 2010 ; Vol. 6, No. 5. pp. 651-661.
@article{dc8d0b75627147f4a53cf850db725774,
title = "Delivery of a peptide via poly(d,l-lactic-co-glycolic) acid nanoparticles enhances its dendritic cell-stimulatory capacity",
abstract = "Nanoparticles (NPs) are attractive carriers for vaccines. We have previously shown that a short peptide (Hp91) activates dendritic cells (DCs), which are critical for initiation of immune responses. In an effort to develop Hp91 as a vaccine adjuvant with NP carriers, we evaluated its activity when encapsulated in or conjugated to the surface of poly(d,. l-lactic-. co-glycolic) acid (PLGA) NPs. We found that Hp91, when encapsulated in or conjugated to the surface of PLGA-NPs, not only activates both human and mouse DCs, but is in fact more potent than free Hp91. Hp91 packaged within NPs was about fivefold more potent than the free peptide, and Hp91 conjugated to the surface of NPs was ~20-fold more potent than free Hp91. Because of their capacity to activate DCs, such NP-Hp91 systems are promising as delivery vehicles for subunit vaccines against infectious disease or cancer. From the Clinical Editor: In this paper, nanoparticle-based dendritic cell activating vaccines are described and discussed. The authors report that the presented PLGA NP based vaccine constructs increase the potency of the studied vaccine by up to 20-fold, making them promising as delivery vehicles for subunit vaccines against infectious diseases or cancer.",
keywords = "Dendritic cells, HMGB1, Immune stimulation, Peptide conjugation, PLGA nanoparticles",
author = "Corbin Clawson and Huang, {Chien Tze} and Diahnn Futalan and {Martin Seible}, Daniel and Rebecca Saenz and Marie Larsson and Wenxue Ma and Boris Minev and Fiona Zhang and Mihri Ozkan and Cengiz Ozkan and Sadik Esener and Davorka Messmer",
year = "2010",
month = "10",
doi = "10.1016/j.nano.2010.03.001",
language = "English (US)",
volume = "6",
pages = "651--661",
journal = "Nanomedicine: Nanotechnology, Biology, and Medicine",
issn = "1549-9634",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Delivery of a peptide via poly(d,l-lactic-co-glycolic) acid nanoparticles enhances its dendritic cell-stimulatory capacity

AU - Clawson, Corbin

AU - Huang, Chien Tze

AU - Futalan, Diahnn

AU - Martin Seible, Daniel

AU - Saenz, Rebecca

AU - Larsson, Marie

AU - Ma, Wenxue

AU - Minev, Boris

AU - Zhang, Fiona

AU - Ozkan, Mihri

AU - Ozkan, Cengiz

AU - Esener, Sadik

AU - Messmer, Davorka

PY - 2010/10

Y1 - 2010/10

N2 - Nanoparticles (NPs) are attractive carriers for vaccines. We have previously shown that a short peptide (Hp91) activates dendritic cells (DCs), which are critical for initiation of immune responses. In an effort to develop Hp91 as a vaccine adjuvant with NP carriers, we evaluated its activity when encapsulated in or conjugated to the surface of poly(d,. l-lactic-. co-glycolic) acid (PLGA) NPs. We found that Hp91, when encapsulated in or conjugated to the surface of PLGA-NPs, not only activates both human and mouse DCs, but is in fact more potent than free Hp91. Hp91 packaged within NPs was about fivefold more potent than the free peptide, and Hp91 conjugated to the surface of NPs was ~20-fold more potent than free Hp91. Because of their capacity to activate DCs, such NP-Hp91 systems are promising as delivery vehicles for subunit vaccines against infectious disease or cancer. From the Clinical Editor: In this paper, nanoparticle-based dendritic cell activating vaccines are described and discussed. The authors report that the presented PLGA NP based vaccine constructs increase the potency of the studied vaccine by up to 20-fold, making them promising as delivery vehicles for subunit vaccines against infectious diseases or cancer.

AB - Nanoparticles (NPs) are attractive carriers for vaccines. We have previously shown that a short peptide (Hp91) activates dendritic cells (DCs), which are critical for initiation of immune responses. In an effort to develop Hp91 as a vaccine adjuvant with NP carriers, we evaluated its activity when encapsulated in or conjugated to the surface of poly(d,. l-lactic-. co-glycolic) acid (PLGA) NPs. We found that Hp91, when encapsulated in or conjugated to the surface of PLGA-NPs, not only activates both human and mouse DCs, but is in fact more potent than free Hp91. Hp91 packaged within NPs was about fivefold more potent than the free peptide, and Hp91 conjugated to the surface of NPs was ~20-fold more potent than free Hp91. Because of their capacity to activate DCs, such NP-Hp91 systems are promising as delivery vehicles for subunit vaccines against infectious disease or cancer. From the Clinical Editor: In this paper, nanoparticle-based dendritic cell activating vaccines are described and discussed. The authors report that the presented PLGA NP based vaccine constructs increase the potency of the studied vaccine by up to 20-fold, making them promising as delivery vehicles for subunit vaccines against infectious diseases or cancer.

KW - Dendritic cells

KW - HMGB1

KW - Immune stimulation

KW - Peptide conjugation

KW - PLGA nanoparticles

UR - http://www.scopus.com/inward/record.url?scp=77957167780&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957167780&partnerID=8YFLogxK

U2 - 10.1016/j.nano.2010.03.001

DO - 10.1016/j.nano.2010.03.001

M3 - Article

C2 - 20348031

AN - SCOPUS:77957167780

VL - 6

SP - 651

EP - 661

JO - Nanomedicine: Nanotechnology, Biology, and Medicine

JF - Nanomedicine: Nanotechnology, Biology, and Medicine

SN - 1549-9634

IS - 5

ER -